Bausch Sues to Block Copies of Trulance Constipation Drug

Bausch and its Salix unit said a generic version of Trulance proposed by closely held MSN Laboratories infringes eight patents for the constipation treatment.

• Bausch is seeking a court order blocking copies until the patents have expired, according to complaint filed Thursday in federal court in Newark, New Jersey
• Patents expire in March and June 2022, January 2028, September 2031 (three), August 2032 and June 2034: FDA Orange Book
• Bausch’s Salix generated nearly a quarter of its 2020 revenue and “may be boosted by the recent launch of Trulance for irritable bowel syndrome with constipation,” Bloomberg Intelligence analyst Ann-Hunter van ...